Recently, Wilms’ tumour 1 protein (WT1), a development-specific transcription factor that contributes to oncogenesis116 and used to be a TAA of other tumours,117,118 has been evaluated in several clinical trials on GBM patients (NCT03149003, NCT02649582, NCT01291420), suggesting that more GBM TAAs can be explored from existing TAAs of other tumours. This evidence concerns the gene WT1 and glioblastoma.